Drug intelligence / Profile preview

RQ-3064

Development stage: Preclinical
Lead developer: RNACure Biopharma
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RQ-3064 is an mRNA vaccine candidate developed by RNAcure (Suzhou RNAcure Health Technology) for the prevention of COVID-19. It is specifically designed to target the JN.1 variant of SARS-CoV-2, which emerged as a dominant strain globally. The vaccine utilizes mRNA technology to instruct host cells to synthesize the viral spike protein, thereby inducing a targeted immune response. RQ-3064 represents a variant-specific update in RNAcure's infectious disease pipeline, aimed at maintaining efficacy against evolving SARS-CoV-2 lineages.

Targets

Severe acute respiratory syndrome coronavirus 2 spike glycoprotein (JN.1 variant)PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on RQ-3064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-3064.

Explore the full profile